基本信息
浏览量:478
职业迁徙
个人简介
Dr. Kari Alitalo is a tenured Research Professor of the Finnish Academy of Sciences and Director of the Wihuri Research Institute and the Centre of Excellence on Translational Cancer Biology in the Faculty of Medicine of the University of Helsinki. He was born in Kuopio, Finland in 1952 and obtained M.D. and Ph.D. from the University of Helsinki in Finland in 1981. He did his posdoctoral studies with Dr. Paul Bornstein in University of Washinton in Seattle, followed by a postdoctoral period with Drs. Michael Bishop and Harold Varmus in University of California in San Francisco. He was appointed as Professor of Medical Biochemistry in Finland in 1986, Research Professor of the Finnish Cancer Institute in 1987, Professor of Cancer Biology in 1988 and Research Professor of the Finnish Academy of Sciences in 1993. He served as the Director of the Molecular/Cancer Biology Research Program starting from 1999, Academy of Finland Center of Excellence in Cancer Biology from 2000, and in his curernt positions since 2013.
Research Interests
Dr. Alitalo is best known for his work on oncogenes and mechanisms of angiogenesis. He discovered lymphangiogenesis its regulation by growth factors, receptors and signaling mechanisms. He has isolated and characterized several tyrosine kinases including the endothelial receptor tyrosine kinase Tie1, which is related to the Tie2 receptor for angiopoietins and implicated in tumor angiogenesis. He cloned the vascular endothelial growth factor (VEGF) receptor-3, purified and cloned its ligand VEGF-C, and showed that the VEGF-C/VEGFR-3 pathway is required for angiogenesis and lymphangiogenesis. He was also central in the cloning and characterization of the VEGF-B. His laboratory is curerntly studying its function as a coronary vascular growth factor and metabolic regulator in the heart. Studies in his laboratory have demonstrated VEGF-C induced tumor angiogenesis and lymphangiogenesis, intralymphatic tumor growth, and VEGF-C association with tumor metastasis and its inhibition by blocking the VEGFR-3 signal transduction pathway. The inhibitors of these pathways from his laboratory have now entered phase I clinical trials. He is also interested in molecular therapies for lymphedema, which are entering clinical trials. Recent work in his laboratory heve also led to studies of the homeobox transcription factor Prox1 in colon carcinoma stem cells and tumor progression.
研究兴趣
论文共 1011 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Salli Antila,Dmitri Chilov,Harri Nurmi,Zhilin Li, Anni Nasi,Maria Gotkiewicz,Valeriia Sitnikova, Henna Jaentti, Natalia Acosta,Hennariikka Koivisto, Jonathan Ray,Meike Hedwig Keuters,
NATURE CARDIOVASCULAR RESEARCH (2024)
Developmental Cellno. 3 (2024): 293-294
Salli Antila,Dmitri Chilov,Harri Nurmi,Zhilin Li, Anni Näsi,Maria Gotkiewicz,Valeriia Sitnikova,Henna Jäntti, Natalia Acosta,Hennariikka Koivisto, Jonathan Ray, Meike Hedwig Keuters,
Nature Cardiovascular Researchpp.1-18, (2024)
DEVELOPMENTAL CELLno. 3 (2024): 293-294
The Journal of clinical investigationno. 4 (2024)
Pauliina Kallio, Elina Jokinen,Jenny Högström,Suvendu Das,Sarika Heino,Marianne Lähde, Jefim Brodkin, Emilia A. Korhonen,Kari Alitalo
crossref(2023)
Tanja Holopainen, Vanessa López- Alpuche,Wei Zheng,Ritva Heljasvaara,Dennis Jones,Yun He,Denis Tvorogov, Gabriela D'Amico, Zoltan Wiener,Leif C. Andersson,Taina Pihlajaniemi,Wang Min,
crossref(2023)
Tanja Holopainen, Vanessa López- Alpuche,Wei Zheng,Ritva Heljasvaara,Dennis Jones,Yun He,Denis Tvorogov, Gabriela D'Amico, Zoltan Wiener,Leif C. Andersson,Taina Pihlajaniemi,Wang Min,
crossref(2023)
Bong-Hyun Jeon,Cholsoon Jang,Jinah Han,Raghu P. Kataru, Lianhua Piao,Keehoon Jung, Hye Ji Cha, Reto A. Schwendener,Kyu Yun Jang, Kwan-Sik Kim,Kari Alitalo, Gou Young Koh
crossref(2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn